Watch Dr Christopher Cannon discuss his study: Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
In patients with atrial fibrillation who have had a percutaneous coronary intervention, the current standard practice is to prescribe “triple therapy” i.e. warfarin plus two antiplatelet agents including an aspirin. However, this is associated with a high risk of bleeding. This ground-breaking trial compares triple therapy with “dual therapy” (dabigatran plus one antiplatelet agent).
This educational activity is designed for cardiologists, surgeons, primary care physicians, GPs, nurses and any other healthcare professional with an interest or role in atrial fibrillation management.
Missed a live event? All journal club recordings can be accessed here to explore or revisit in your own time via our eLearning platform.